Interview Highlights: Steve Brozak of WBB Securities on Biotechnology and Pharmaceuticals

August 25, 2016

Steve Brozak specializes in health research and banking across many segments. Right now Mr. Brozak is seeing one of the most significant demands for innovation. He says there is a limited availability of money to fund research and pay for drugs, and he is seeing more financial calculations based on revenue that shouldn’t be rewarded, as well as companies making incremental improvements of older drugs being rewarded. He says resources are being wasted to support these types of activities. Mr. Brozak is looking forward to seeing some pushback, and he’s starting to see some around the periphery. He discusses five companies with novel drugs that investors should be noting.

Full interview available here.